SCHEMBL16701418

SCHEMBL16701418

Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2CCNCc1ccccc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 16/20 0.67
LCK P06239 5/20 0.67
ITK Q08881 3/20 0.67
EGFR P00533 2/20 0.67
JAK3 P52333 2/20 0.67
NUDT14 O95848 1/20 0.65
NUDT5 Q9UKK9 1/20 0.65
PIK3CD O00329 3/20 0.58
PIK3CA P42336 3/20 0.58
PIK3CB P42338 3/20 0.58
PIK3CG P48736 3/20 0.58
PRKDC P78527 3/20 0.58
FYN P06241 6/20 0.55
MAP2K5 Q13163 3/20 0.55
LYN P07948 5/20 0.54
SRC P12931 4/20 0.54
FLT3 P36888 4/20 0.54
PTK6 Q13882 4/20 0.54
HCK P08631 3/20 0.54
FGR P09769 3/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25069009 0.89 NUDT14 (0.69) BTKLCKITKEGFRJAK3
SCHEMBL22909341 0.87 NUDT14 (0.72) BTKLCKITKEGFRJAK3
SCHEMBL28407363 0.84 BTK (0.89) BTKLCKITKEGFRJAK3
SCHEMBL29665672 0.84 BTK (0.72) BTKLCKITKEGFRJAK3
SCHEMBL13861437 0.84 BTK (0.72) BTKLCKITKEGFRJAK3
SCHEMBL25069017 0.84 NUDT14 (0.68) BTKLCKITKEGFRJAK3
SCHEMBL15517319 0.84 BTK (0.81) BTKLCKITKEGFRJAK3
SCHEMBL17090646 0.83 BTK (0.80) BTKLCKITKEGFRJAK3
SCHEMBL16448087 0.83 BTK (0.70) BTKLCKITKEGFRJAK3
Hydrochloric Acid SCHEMBL29665759 0.83 BTK (0.70) BTKLCKITKEGFRJAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160272645-A1 Heterocyclic Compounds and Methods of Use MEDIVATION TECHNOLOGIES, INC. (US) 2016-09-22 US disclosed
WO-2015069441-A1 PYRAZOLO-, IMIDAZOLO- AND PYRROLO-PYRIDINE OR -PYRIMIDINE DERIVATIVES AS INHIBITORS O BRUTONS KINASE (BTK) MEDIVATION TECHNOLOGIES, INC. (US) 2015-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160272645-A1 Heterocyclic Compounds and Methods of Use BTK, PIK3CD, PIK3CB BTK 1/4885LCK 51/4885ITK 390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.